Idioma:

Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors

Binder, Joseph ; Tetangco, Selwyna ; Weinshank, Megan ; Maegley, Karen ; Lingardo, Laura ; Diehl, Wade ; Love, Robert ; Patick, Amy K. ; Smith, George J.

Antiviral research, 2011-08, Vol.91 (2), p.102-111 [Periódico revisado por pares]

Kidlington: Elsevier B.V

Texto completo disponível

Citações Citado por

Enviar para

Título:
Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors
Autor: Binder, Joseph ; Tetangco, Selwyna ; Weinshank, Megan ; Maegley, Karen ; Lingardo, Laura ; Diehl, Wade ; Love, Robert ; Patick, Amy K. ; Smith, George J.
Assuntos: Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - chemistry ; Antiviral Agents - pharmacology ; Base Sequence ; Binding Sites ; Biological and medical sciences ; Carbamates - chemistry ; Carbamates - pharmacology ; Cell Line ; Chimeric replicon ; Cloning, Molecular ; Fluorescence Resonance Energy Transfer - methods ; Genetic Variation ; Genetic Vectors - genetics ; Genotype ; HCV ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepacivirus - physiology ; Hepatitis C virus ; Humans ; Macrocyclic Compounds - chemistry ; Macrocyclic Compounds - pharmacology ; Medical sciences ; Microbial Sensitivity Tests ; NS3 protease ; Oligopeptides - chemistry ; Oligopeptides - pharmacology ; Pharmacology. Drug treatments ; Phylogeny ; Protease Inhibitors - chemistry ; Protease Inhibitors - pharmacology ; Quinolines - chemistry ; Quinolines - pharmacology ; Replicon ; Sequence Analysis, Protein - methods ; Thiazoles - chemistry ; Thiazoles - pharmacology ; Viral Nonstructural Proteins - antagonists & inhibitors ; Viral Nonstructural Proteins - chemistry ; Virus Replication
É parte de: Antiviral research, 2011-08, Vol.91 (2), p.102-111
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
Descrição: Several potent inhibitors of hepatitis C virus (HCV) NS3/4A protease have been identified that show great clinical potential against genotype 1. Due to the tremendous genetic diversity that exists among HCV isolates, development of broad spectrum inhibitors is challenging. With a limited number of lab strains available for preclinical testing, new tools are required for assessing protease inhibitor activity. We developed a chimeric replicon system for evaluating NS3 protease inhibitor activity against naturally occurring isolates. NS3/4A genes were cloned from the plasma of HCV-infected individuals and inserted into lab strain replicons, replacing the native sequences. The chimeric reporter replicons were transfected into Huh 7.5 cells, their replication monitored by luciferase assays, and their susceptibilities to inhibitors determined. Viable chimeras expressing heterologous genotypes 1, 2, 3, and 4 protease domains were identified that exhibited varying susceptibilities to inhibitors. Protease inhibitor spectrums observed against the chimeric replicon panel strongly correlated with published enzymatic and clinical results. This cell-based chimeric replicon system can be used to characterize the activities of protease inhibitors against diverse natural isolates and may improve the ability to predict dose and clinical efficacy.
Editor: Kidlington: Elsevier B.V
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors

Binder, Joseph ; Tetangco, Selwyna ; Weinshank, Megan ; Maegley, Karen ; Lingardo, Laura ; Diehl, Wade ; Love, Robert ; Patick, Amy K. ; Smith, George J.

Kidlington: Elsevier B.V

Buscando em bases de dados remotas. Favor aguardar.